Medication reconciliation: before vs at admission
Identified discrepancies per patient ( · adults
1 finding from 1 review
- no estimate extracted1 study · 307 participantsLow
Findings
What do systematic reviews say?
1,281 questions · 1,307 findings · 212 reviews
No studies found 256 · 19.6%GRADE not reported 125 · 9.6%Very low 266 · 20.4%Low 403 · 30.8%Moderate 208 · 15.9%High 49 · 3.7%
Medication reconciliation: pharmacist vs other professionals
Patient readmissions · adults
Medication reconciliation: pharmacist showed no clear difference in readmission at 1 month ( compared with other professionals (moderate certainty).
1 finding from 1 review
- RR 0.93 [0.76, 1.14]2 studies · 997 participantsModerate
Medication reconciliation: pharmacist vs other professionals
Length of stay · adults
1 finding from 1 review
- no estimate extracted6 studies · 3983 participantsLow
Medication reconciliation: pharmacist vs other professionals
Quality of life (VAS 0‐10; EQ‐5D‐3L) ( · adults
1 finding from 1 review
- no estimate extracted1 study · 724 participantsLow
Medication reconciliation: pharmacist vs other professionals
Discrepancy resolution ( · adults
Medication reconciliation: pharmacist may leads to higher discrepancy resolution ( compared with other professionals (low certainty).
1 finding from 1 review
- OR 4.8 [1.81, 12.76]3 studies · 1449 participantsLow
Medication reconciliation: pharmacist vs other professionals
ADEs ( · adults
Medication reconciliation: pharmacist showed no clear difference in ADEs ( compared with other professionals (low certainty).
1 finding from 1 review
- OR 1.34 [0.73, 2.44]3 studies · 2873 participantsLow
Medication reconciliation: pharmacist vs other professionals
Mortality during hospitalisation ( · adults
Medication reconciliation: pharmacist showed no clear difference in mortality during hospitalisation ( compared with other professionals (moderate certainty).
1 finding from 1 review
- RR 0.99 [0.57, 1.73]2 studies · 1000 participantsModerate
Medication reconciliation interventions vs usual care
PADEs · all patients (aged > 18 years) at a transition of care
It is very uncertain whether medication reconciliation interventions changes PADEs compared with standard care (very low certainty).
1 finding from 1 review
- Impact of medication reconciliation for improving transitions of care 2018 · Cochrane Headline outcomes onlyRR 0.37 [0.09, 1.57]3 studies · 1253 participantsVery low
Medication reconciliation interventions vs usual care
ADEs ( · all patients (aged > 18 years) at a transition of care
Medication reconciliation interventions showed no clear difference in ADEs compared with standard care (low certainty).
1 finding from 1 review
- Impact of medication reconciliation for improving transitions of care 2018 · Cochrane Headline outcomes onlyRR 1.09 [0.91, 1.3]4 studies · 1363 participantsLow
Medication reconciliation interventions vs usual care
Unplanned rehospitalisation · all patients (aged > 18 years) at a transition of care
Medication reconciliation interventions showed no clear difference in unplanned rehospitalisation compared with standard care (moderate certainty).
1 finding from 1 review
- Impact of medication reconciliation for improving transitions of care 2018 · Cochrane Headline outcomes onlyRR 0.72 [0.44, 1.18]5 studies · 1206 participantsModerate
Medication reconciliation interventions vs usual care
Hospital usage (composite measure of ED, rehospitalisation) · all patients (aged > 18 years) at a transition of care
It is very uncertain whether medication reconciliation interventions changes hospital usage (composite measure of ED, rehospitalisation) compared with standard care (very low certainty).
1 finding from 1 review
- Impact of medication reconciliation for improving transitions of care 2018 · Cochrane Headline outcomes onlyRR 0.78 [0.5, 1.22]4 studies · 597 participantsVery low
Supervised dosing with a long‐acting medication vs unsupervised consumption
Retention [ · patients with opioid dependence
Supervised dosing with a long‐acting medication showed no clear difference in retention ‐ retention at the end of treatment (number of participants) compared with unsupervised consumption (low certainty).
2 findings from 1 review
- Supervised dosing with a long‐acting opioid medication in the management of opioid dependence 2017 · Cochrane Headline outcomes onlyRR 0.99 [0.88, 1.12]4 studies · 716 participantsLow
- Supervised dosing with a long‐acting opioid medication in the management of opioid dependence 2017 · Cochrane Headline outcomes onlyRR 0.94 [0.84, 1.05]3 studies · 472 participantsLow
Supervised dosing with a long‐acting medication vs unsupervised consumption
Adverse serious events (any) (number of participants) · patients with opioid dependence
It is very uncertain whether supervised dosing with a long‐acting medication changes adverse serious events (any) (number of participants) compared with unsupervised consumption (very low certainty).
1 finding from 1 review
- Supervised dosing with a long‐acting opioid medication in the management of opioid dependence 2017 · Cochrane Headline outcomes onlyRR 0.63 [0.1, 3.86]2 studies · 363 participantsVery low
Supervised dosing with a long‐acting medication vs unsupervised consumption
Abstinence from unsanctioned opioid use (number of participants with urine drug screen or self‐report use) · patients with opioid dependence
1 finding from 1 review
- Supervised dosing with a long‐acting opioid medication in the management of opioid dependence 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 293 participantsVery low
Supervised dosing with a long‐acting medication vs unsupervised consumption
Diversion (number of participants) · patients with opioid dependence
1 finding from 1 review
- Supervised dosing with a long‐acting opioid medication in the management of opioid dependence 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 293 participantsVery low
Supervised dosing with a long‐acting medication vs unsupervised consumption
Days of unsanctioned opioid use · patients with opioid dependence
1 finding from 1 review
- Supervised dosing with a long‐acting opioid medication in the management of opioid dependence 2017 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
Supervised dosing with a long‐acting medication vs unsupervised consumption
Mortality ‐ (number of participants) · patients with opioid dependence
1 finding from 1 review
- Supervised dosing with a long‐acting opioid medication in the management of opioid dependence 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 230 participantsLow
Pre‐emptive medication vs prophylaxis
Acute rejection · solid organ transplant recipients with CMV viraemia
1 finding from 1 review
- Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant… 2013 · Cochrane Headline outcomes onlyno estimate extracted6 studies · 693 participantsLow
Pre‐emptive medication vs prophylaxis
Leucopenia · solid organ transplant recipients with CMV viraemia
1 finding from 1 review
- Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant… 2013 · Cochrane Headline outcomes onlyno estimate extracted6 studies · 729 participantsModerate
Pre‐emptive medication vs prophylaxis
D+/R‐ serostatus: symptomatic CMV · solid organ transplant recipients with CMV viraemia
1 finding from 1 review
- Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant… 2013 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 39 participantsVery low